Protom International

About Protom International

Protom International, founded in 2008, operates in the medical technology sector with a specific focus on making proton therapy a more accessible and financially viable option for cancer treatment. The company is headquartered in Flower Mound, Texas, and serves a global market of hospitals and physician groups looking to establish their own proton therapy centers. Protom International's business model centers on the manufacturing, sale, and distribution of its proprietary proton therapy systems, generating revenue through system sales and long-term service contracts.

The company was brought to life by a team that includes Stephen Spotts, who has served as CEO, and Dmitri Sivan, a founding member with over two decades of experience in the proton therapy field. Paul Tso, an early investor with extensive experience in developing growth strategies for early-stage companies, was appointed CEO in January 2024. The leadership team's collective experience in healthcare, technology, and business development underpins the company's mission. A notable, though challenging, milestone was the company's filing for bankruptcy protection, as reported by industry media.

Protom International's core offering is the Radiance 330® Proton Therapy System. This system is engineered to be compact and modular, allowing for installation in facilities where larger, more conventional systems would not fit, including within existing radiation oncology departments. A key feature is its synchrotron particle accelerator, which is smaller than those of many competitors and provides a clinical treatment energy range of 70 to 250 MeV. The system utilizes pencil-beam scanning for precise targeting of tumors, which helps to minimize radiation exposure to surrounding healthy tissues and vital organs. This precision can lead to fewer side effects and improved quality of life for patients. The Radiance 330® has received FDA 510(k) clearance, enabling its commercial distribution in the United States. Protom aims to lower both the capital and operating costs typically associated with proton therapy, thereby improving the return on investment for healthcare providers.